{"id":121746,"date":"2026-02-27T17:24:58","date_gmt":"2026-02-27T17:24:58","guid":{"rendered":"https:\/\/www.atlasrleye.com\/?page_id=121746"},"modified":"2026-02-28T19:22:32","modified_gmt":"2026-02-28T19:22:32","slug":"in-rethinopathy-of-prematurity","status":"publish","type":"page","link":"https:\/\/www.atlasrleye.com\/en\/in-rethinopathy-of-prematurity\/","title":{"rendered":"IN RETHINOPATHY OF PREMATURITY"},"content":{"rendered":"

[vc_row][vc_column][vc_custom_heading text=”IN RETHINOPATHY OF PREMATURITY” font_container=”tag:h5|font_size:44px|text_align:center|color:%235f1b52″ google_fonts=”font_family:Average%20Sans%3Aregular|font_style:400%20regular%3A400%3Anormal” css=””]

<\/div>[\/vc_column][\/vc_row][vc_row][vc_column width=”2\/3″][vc_column_text css=””]<\/p>\n
\n

A introdu\u00e7\u00e3o dos f\u00e1rmacos anti-VEGF na Oftalmologia representou uma mudan\u00e7a importante no tratamento da retinopatia do prematuro (ROP).<\/p>\n

O tratamento padr\u00e3o baseava-se quase exclusivamente na fotocoagula\u00e7\u00e3o a laser da retina avascular, um m\u00e9todo eficaz na estabiliza\u00e7\u00e3o da doen\u00e7a, mas associado a destrui\u00e7\u00e3o tecidular e a altera\u00e7\u00f5es a longo prazo no campo visual.<\/p>\n

Como n\u00e3o existiam op\u00e7\u00f5es terap\u00eauticas eficazes para estes casos e com uma melhor compreens\u00e3o do papel central do fator de crescimento endotelial vascular (VEGF) na patog\u00e9nese da ROP, o anti-VEGF bevacizumab, inicialmente aprovado para oncologia, foi utilizado pela primeira vez em Oftalmologia por Ant\u00f3nio Travassos, em regime off-label mas de forma consciente e respons\u00e1vel. A injec\u00e7\u00e3o intrav\u00edtrea de um volume reduzido de bevacizumab (0,03 ml) em prematuros demonstrou efic\u00e1cia cl\u00ednica e seguran\u00e7a, estabelecendo uma nova abordagem terap\u00eautica para a retinopatia do prematuro. <\/p>\n

 <\/p>\n

References:<\/p>\n

Intravitreal Bevacizumab in Aggressive Posterior Retinopathy of Prematurity.<\/p>\n

Ant\u00f3nio Travassos, MD, Susana Teixeira, MD, Pinto Ferreira, MD, Isaura Regadas, MD, Ana Sofia Travassos, MD et col.<\/p>\n

Ophthalmic Surgery, Lasers and Imaging Retina38(3):233\u2013237<\/p>\n

https:\/\/doi.org\/10.3928\/15428877-20070501-09<\/a><\/p>\n

 <\/p>\n

Acompanhe os casos cl\u00ednicos em:<\/p>\n

https:\/\/www.atlasrleye.com\/doencas-congenitas-e-pediatricas-da-retina\/retinopatia-do-prematuro\/<\/a><\/p>\n

 <\/p>\n

Saiba mais em:<\/p>\n

https:\/\/ccci.pt\/terapeutica-que-veio-agitar-oftalmologia-2<\/a><\/p>\n<\/div>\n

[\/vc_column_text][\/vc_column][vc_column css_animation=”none” width=”1\/3″][vc_single_image image=”118998″ img_size=”full” onclick=”custom_link” img_link_target=”_blank” css=”” link=”https:\/\/www.atlasrleye.com\/wp-content\/uploads\/2024\/03\/WP_Glaucoma-Automatic-Diagnosis-1.pdf”][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column][vc_custom_heading text=”IN RETHINOPATHY OF PREMATURITY” font_container=”tag:h5|font_size:44px|text_align:center|color:%235f1b52″ google_fonts=”font_family:Average%20Sans%3Aregular|font_style:400%20regular%3A400%3Anormal” css=””][\/vc_column][\/vc_row][vc_row][vc_column width=”2\/3″][vc_column_text css=””] A introdu\u00e7\u00e3o dos f\u00e1rmacos anti-VEGF na Oftalmologia representou uma mudan\u00e7a importante no tratamento da retinopatia do prematuro (ROP). O tratamento padr\u00e3o baseava-se quase exclusivamente na fotocoagula\u00e7\u00e3o a laser da retina […]<\/p>\n","protected":false},"author":5,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-121746","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/pages\/121746","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/comments?post=121746"}],"version-history":[{"count":10,"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/pages\/121746\/revisions"}],"predecessor-version":[{"id":121801,"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/pages\/121746\/revisions\/121801"}],"wp:attachment":[{"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/media?parent=121746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}